We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals
NRXP

20 hedge funds and large institutions have $44.1M invested in NRX Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

6% more capital invested

Capital invested by funds: $41.4M → $44.1M (+$2.66M)

5% more funds holding

Funds holding: 19 → 20 (+1)

0.25% more ownership

Funds ownership: 4.73% → 4.98% (+0.25%)

Holders
20
Holders Change
+1
Holders Change %
+5.26%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LIM
Longfellow Investment Management
Massachusetts
+$966K
2
RCM
Rivernorth Capital Management
Florida
+$596K
3
BI
Bulldog Investors
New Jersey
+$394K
4
OAM
Oxford Asset Management
United Kingdom
+$348K
5
HCMT
Highland Capital Management (Texas)
Texas
+$240K

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$201K
2
KPF
K2 Principal Fund
Ontario, Canada
-$121K
3
KIM
Karpus Investment Management
New York
-$18.9K
4
UBS Group
UBS Group
Switzerland
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
HIM
1
HGC Investment Management
Ontario, Canada
$4.82M +$49.8K +500 +1%
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$4.69M – – –
OAM
3
Oxford Asset Management
United Kingdom
$4.47M +$348K +3,500 +8%
Bank of Montreal
4
Bank of Montreal
Ontario, Canada
$3.53M – – –
BFM
5
Boothbay Fund Management
New York
$3.01M – – –
BI
6
Bulldog Investors
New Jersey
$2.85M +$394K +3,956 +16%
PC
7
Periscope Capital
Ontario, Canada
$2.53M – – –
KIM
8
Karpus Investment Management
New York
$2.51M -$18.9K -190 -0.8%
WCMNY
9
Westchester Capital Management (New York)
New York
$2.45M – – –
RCM
10
Rivernorth Capital Management
Florida
$2.4M +$596K +5,992 +33%
WRBC
11
W.R. Berkley Corp
Connecticut
$2.03M – – –
AA
12
AQR Arbitrage
Connecticut
$2M – – –
GCL
13
Glazer Capital LLC
New York
$1.72M -$201K -2,020 -11%
YCM
14
Yakira Capital Management
Connecticut
$1.65M – – –
KPF
15
K2 Principal Fund
Ontario, Canada
$1.34M -$121K -1,220 -8%
LIM
16
Longfellow Investment Management
Massachusetts
$972K +$966K +9,707 New
BCM
17
Basso Capital Management
Connecticut
$537K – – –
HCMT
18
Highland Capital Management (Texas)
Texas
$516K +$240K +2,413 +88%
BCM
19
Bluefin Capital Management
New York
$32K – – –
Walleye Trading
20
Walleye Trading
New York
$3K +$2.98K +30 New
UBS Group
21
UBS Group
Switzerland
– -$13K -130 Closed

NRXP Hedge Fund Activity: Q3 2018 in Review

20 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q3 2018, worth a combined $44.1M — up 6.4% from $41.4M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new NRXP positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Longfellow Investment Management, opening a new position worth an estimated $966K. The largest seller was Glazer Capital LLC, cutting an estimated $201K.

  • 20 institutional investors held NRX Pharmaceuticals (NRXP) as of Q3 2018, up from 19 in Q2 2018.
  • Funds reported $44.1M of NRX Pharmaceuticals stock for Q3 2018, up 6.4% quarter-over-quarter.
  • 2 funds opened new NRX Pharmaceuticals positions in Q3 2018 and 1 closed out, a net change of +1 holder.
  • The largest NRX Pharmaceuticals buyer in Q3 2018 was Longfellow Investment Management, an estimated $966K added.
  • The largest NRX Pharmaceuticals seller in Q3 2018 was Glazer Capital LLC, an estimated $201K sold.

Based on aggregated 13F filings for Q3 2018.